What is Injection Bevacizumab 0 25 Mg (HCPCS C9257)?

Injection, bevacizumab, 0.25 mg. This clinical code is utilized across practices and hospitals for diagnostic and therapeutic service documentation.

What do doctors typically charge for Injection Bevacizumab 0 25 Mg?

The nationwide median physician charge for Injection Bevacizumab 0 25 Mg (HCPCS C9257) is $33.30. Doctor billed charges vary based on geographic region, setting, and overhead.

What is the standard insurance baseline for HCPCS C9257?

The standard insurance baseline reimbursement rate is $1.78. This represents the customary allowable amount established across standard fee schedules.

Home/Procedures/Injection Bevacizumab 0 25 Mg

HCPCS C9257Medical Service

Injection Bevacizumab 0 25 Mg

Injection, bevacizumab, 0.25 mg. Clinical pricing breakdown and utilization metrics across 10 practicing doctors nationwide.

$33.30

Peer Median Charge

Gross billed rate

$1.78

Standard Baseline

Customary allowable

18.7x

National Markup

Charge vs baseline

Active Physicians

Billing this code

Planning care or already received a bill for CPT C9257?Calculate total facility bundle costs or generate an assertive dispute settlement offer.

Calculate Bundled Cost →Dispute an Inflated Bill 🧾

Understanding This Medical Fee

Gross Charge vs Negotiated Payment: The median physician charge for this service is $33.30. However, insured patients almost never pay this full amount directly. Insurers negotiate rates down toward the $1.78 baseline.

Self-Pay & Uninsured Guidance: If you are paying without insurance or out-of-network, request a prompt-pay cash discount. Most medical practices are willing to settle self-pay bills near the customary baseline rate rather than the full gross charge.

Key Questions for Your Doctor's Billing Office:

"Does Dr. [Name] participate in my specific insurance plan network?"
"What is the total self-pay or cash rate for code C9257 if paid upfront?"
"Are there separate facility, anesthesia, or pathology fees associated with this procedure?"